NO952624L - Antihyperglykemisk aktivt legemiddel - Google Patents

Antihyperglykemisk aktivt legemiddel

Info

Publication number
NO952624L
NO952624L NO952624A NO952624A NO952624L NO 952624 L NO952624 L NO 952624L NO 952624 A NO952624 A NO 952624A NO 952624 A NO952624 A NO 952624A NO 952624 L NO952624 L NO 952624L
Authority
NO
Norway
Prior art keywords
antihyperglycemically
active drug
prepn
antihyperglycaemically
methoxypyrimidine
Prior art date
Application number
NO952624A
Other languages
English (en)
Other versions
NO307029B1 (no
NO952624D0 (no
Inventor
Elbert Kaan
Dieter Ziegler
Reinhard Bruckner
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Publication of NO952624D0 publication Critical patent/NO952624D0/no
Publication of NO952624L publication Critical patent/NO952624L/no
Publication of NO307029B1 publication Critical patent/NO307029B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
NO19952624A 1994-07-01 1995-06-30 Anvendelse av 4-klor-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-metoksy-2-metylpyrimidin til fremstilling av farmasoytiske preparater for behandling av hyperglykemier NO307029B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (3)

Publication Number Publication Date
NO952624D0 NO952624D0 (no) 1995-06-30
NO952624L true NO952624L (no) 1996-01-02
NO307029B1 NO307029B1 (no) 2000-01-31

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19952624A NO307029B1 (no) 1994-07-01 1995-06-30 Anvendelse av 4-klor-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-metoksy-2-metylpyrimidin til fremstilling av farmasoytiske preparater for behandling av hyperglykemier

Country Status (23)

Country Link
US (1) US5712283A (no)
EP (1) EP0689837B1 (no)
JP (1) JP3841846B2 (no)
KR (1) KR100366130B1 (no)
CN (1) CN1092961C (no)
AT (1) ATE210444T1 (no)
AU (1) AU691580B2 (no)
CA (1) CA2152998C (no)
CZ (1) CZ287563B6 (no)
DE (2) DE4423177A1 (no)
DK (1) DK0689837T3 (no)
DZ (1) DZ1894A1 (no)
ES (1) ES2167385T3 (no)
FI (1) FI117374B (no)
HU (1) HU226946B1 (no)
IL (1) IL113411A (no)
NO (1) NO307029B1 (no)
NZ (1) NZ270990A (no)
PT (1) PT689837E (no)
RU (1) RU2145857C1 (no)
SK (1) SK282227B6 (no)
UA (1) UA27954C2 (no)
ZA (1) ZA954691B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0812197A2 (en) * 1995-02-28 1997-12-17 Beiersdorf-Lilly GmbH Use of moxonidine for the treatment of atherosclerosis
WO1997046241A1 (en) * 1996-06-06 1997-12-11 Eli Lilly And Company Formulation and method for treating congestive heart failure
ZA981029B (en) * 1997-02-11 1999-08-10 Lilly Co Eli Pharmaceutical agents.
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
US6897019B1 (en) 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
EP1517688A2 (de) * 2002-06-19 2005-03-30 Solvay Pharmaceuticals GmbH Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
ZA200601804B (en) * 2003-10-10 2007-05-30 Solvay Pharm Gmbh Pharmaceutcal composition comprising a selective II imidazoline receptor agonist and an angiotensin II receptor blocker
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
CZ139395A3 (en) 1996-01-17
NO307029B1 (no) 2000-01-31
SK74995A3 (en) 1996-05-08
DZ1894A1 (fr) 2002-02-17
DE59509928D1 (de) 2002-01-24
HU9501900D0 (en) 1995-08-28
US5712283A (en) 1998-01-27
CA2152998C (en) 2002-09-03
FI117374B (fi) 2006-09-29
HUT72599A (en) 1996-05-28
AU691580B2 (en) 1998-05-21
AU1775795A (en) 1996-01-18
KR100366130B1 (ko) 2003-03-26
EP0689837B1 (de) 2001-12-12
CA2152998A1 (en) 1996-01-02
RU2145857C1 (ru) 2000-02-27
JP3841846B2 (ja) 2006-11-08
SK282227B6 (sk) 2001-12-03
IL113411A (en) 1999-07-14
ATE210444T1 (de) 2001-12-15
CN1122224A (zh) 1996-05-15
HU226946B1 (en) 2010-03-29
KR960003729A (ko) 1996-02-23
NZ270990A (en) 1997-06-24
EP0689837A2 (de) 1996-01-03
CN1092961C (zh) 2002-10-23
FI953256A (fi) 1996-01-02
DE4423177A1 (de) 1996-01-04
FI953256A0 (fi) 1995-06-30
PT689837E (pt) 2002-04-29
IL113411A0 (en) 1995-07-31
JPH0840906A (ja) 1996-02-13
CZ287563B6 (en) 2000-12-13
EP0689837A3 (de) 1996-06-05
NO952624D0 (no) 1995-06-30
UA27954C2 (uk) 2000-10-16
DK0689837T3 (da) 2002-03-11
ZA954691B (en) 1996-01-29
ES2167385T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
ES2139638T3 (es) 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.
DE59010810D1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
ATE87481T1 (de) Orale arzneimittelformen von pimobendan.
FI953256A0 (fi) Hyperglykemian vastaisesti vaikuttava lääkeaine
ZA874812B (en) Drug
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
EP0471388A3 (de) Mittel zur Behandlung der Herzinsuffizienz
GR861646B (en) 4-amino-2-(imidazolidin-2-on-1-yl)-pyrimidino-5-carbonic acid -(n-triphthoro - methyl-phenyl)-amides for antithrombotic protection and treatment use and preparation of antithrombotically active medicines
ES2117114T3 (es) Nuevos derivados de tiaxolidin-diona, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE69106276D1 (de) Säureadditionssalze einer optisch aktiven Alaninanilidverbindung und diese enthaltende, pharmazeutische Zusammensetzungen.
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
ATE138805T1 (de) Substituiertes benzofuranylpiperidin als nootropikum
JPS6434920A (en) Therapy for mycobacterium abium intracellular complex infection
DE3674060D1 (de) Pharmacologisch aktive propionylanilide.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE

MM1K Lapsed by not paying the annual fees